Inovio Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inovio Pharmaceuticals, Inc.
Direct purchasers of drugs from a trio of generics manufacturers in the US say they will receive payments that are fair and reasonable, under settled agreements that have been put before a judge in Pennsylvania.
Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.
The biotech sector is so diverse that for every acquisition there will be at least one second-best. Even after years of independence following a drug approval, investors keep hoping that their pharmaceutical Prince Charming will arrive.
Public Company Edition: Discussions at the J.P. Morgan Healthcare Conference 8-11 January in San Francisco should offer some insight on industry’s and investors’ expectations about the financial markets in 2024. The year started with some big financings, but also some new job cuts.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Bioject Medical Technologies
- Inovio Biomedical
- VGX Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.